{"id":3846,"date":"2025-05-13T17:38:41","date_gmt":"2025-05-13T14:38:41","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3846"},"modified":"2025-05-13T17:47:11","modified_gmt":"2025-05-13T14:47:11","slug":"elevidys-gene-therapy-approved-in-japan","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/elevidys-gene-therapy-approved-in-japan\/","title":{"rendered":"Sarepta Therapeutics annonce l&#039;approbation au Japon d&#039;ELEVIDYS, une th\u00e9rapie g\u00e9nique pour traiter la dystrophie musculaire de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Les personnes \u00e2g\u00e9es de 3 \u00e0 moins de 8 ans, exemptes de d\u00e9l\u00e9tions dans les exons 8 et\/ou 9 du g\u00e8ne DMD et pr\u00e9sentant un test n\u00e9gatif aux anticorps anti-AAVrh74, peuvent utiliser ELEVIDYS. Il s&#039;agit de la premi\u00e8re autorisation mondiale couvrant les personnes de moins de 4 ans.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Apprendre encore plus:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/fr\/frequently-asked-questions-about-elevidys-used-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Questions fr\u00e9quemment pos\u00e9es sur Elevidys utilis\u00e9 pour la dystrophie musculaire de Duchenne<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">La th\u00e9rapie g\u00e9nique ELEVIDYS approuv\u00e9e au Japon<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Sarepta Therapeutics, leader de la m\u00e9decine g\u00e9n\u00e9tique de pr\u00e9cision pour les maladies rares, a annonc\u00e9 aujourd&#039;hui que le minist\u00e8re japonais de la Sant\u00e9, du Travail et des Affaires sociales (MHLW) a approuv\u00e9 ELEVIDYS (delandistrogene moxeparvovec) pour le traitement de la dystrophie musculaire de Duchenne (DMD) dans le cadre de la voie d&#039;approbation conditionnelle et limit\u00e9e dans le temps au Japon.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En savoir plus:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/fr\/will-elevidys-receive-approval-from-the-european-medicines-agency-ema\/\">Le Elevidys recevra-t-il l\u2019approbation de l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA) ?<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>People aged 3 to under 8 who do not have deletions in exons 8 and\/or 9 of the DMD gene and who test negative for anti-AAVrh74 antibodies are eligible to use ELEVIDYS. This is the first worldwide approval that covers people under the age of four. Learn More: Frequently Asked Questions About Elevidys Used for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3847,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[33,61,142],"class_list":["post-3846","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevidys","tag-gene-therapy","tag-japan"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=3846"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3846\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/3847"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=3846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=3846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=3846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}